logo
Plus   Neg
Share
Email

Rio Tinto:well Placed To Benefit From Copper's Attractive Long-term Fundamentals

Rio Tinto PLC (RTPPF.PK,RIO.L,RIO,RTNTF.PK) said that it is well placed to benefit from copper's attractive long-term fundamentals. Market remains finely balanced despite healthy mine performance since the sond-quarterof 17, underscoring solid demand. Rio Tinto copper growth will be delivered into a period that requires development of higher-cost projects.

Current year demand is above trend growth (2.8% year-over-year) on outperforming Chinese end-use and OECD prolonged industrial production cycle. Further demand growth is expected in China and other emerging markets to drive consumption expansion.
The company noted that 1.6 million tonnes of annual production will be lost as mines close between now and 2023.

Committed projects are expected to deliver an additional 1.5 million tones of supply by 2023. Uncommitted projects will need to deliver a further 1.7 million tonnes of copper by 2023 to fill the supply gap.

UG mine and open pit scheduled to deliver on average 560 thousand tonnes of copper per year between 2025 and 2030.

Rio Tinto signed a binding agreement to sell its entire interest in the Grasberg mine to PT Indonesia Asahan Aluminium (Persero) (Inalum), Indonesia's state mining company, for $3.5 billion. The Completion is expected in first half of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT